15,000 second chances: Bone Marrow Transplant program celebrates new milestone

April 24, 2019 | Michael Easterling and Samantha Bonar

City of Hope’s bone marrow transplant program recently performed the procedure on its 15,000th patient, a remarkable milestone considering that the initiative started with just two physicians, three beds and guarded expectations in 1976.

Continue Reading

City of Hope Physicians Announce New CAR T Breakthroughs at Annual ASH Meeting

December 14, 2017 | Letisia Marquez

New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.

Combination Immunotherapy Shown to Be Effective Initial Treatment for Relapsed or Refractory Hodgkin Lymphoma

December 11, 2017 | Katie Neith

Researchers led by Alex Herrera, M.D. have found that a combination of two immunotherapy drugs may be a more tolerable way for patients to fight the disease before a transplant.

Trial Results Point to Promising Treatments for Hodgkin Lymphoma Patients

January 9, 2017 | Abe Rosenberg

Everything changed when Hodgkin lymphoma patient Lowell Winer joined a phase 2 clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.

When Hodgkin Lymphoma returns, a new drug may offer hope

August 16, 2016 | Letisia Marquez

Patients whose Hodgkin lymphoma has returned after a stem cell transplant have few treatment options available but a new drug tested at City of Hope may change that. ABC-7 in Los Angeles featured research by Robert Chen, M.D., on the use of the new medication – brentuximab vedotin (BV) – by these patients.

Research suggests brentuximab vedotin potentially curative in some Hodgkin lymphoma patients with limited treatment options

July 18, 2016 | City of Hope

Study, published in Blood, reports on five-year survival data, suggests targeted therapy should be standard of care for patients with relapsed or treatment-resistant Hodgkin lymphoma.